Weight loss drug and heart ablation study for AFib
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled for your first heart ablation for atrial fibrillation.
- You have a body mass index (BMI) of 30 or higher, OR a BMI of 27 or higher along with conditions like prediabetes, type 2 diabetes, high blood pressure, high cholesterol, heart or blood vessel disease, or sleep apnea.
- If you could become pregnant, you must have a negative pregnancy test and agree to use highly effective birth control during the study.
- You cannot have had a prior heart ablation or be currently using certain diabetes medications like GLP-1 agonists, dual agonists, or DPP-IV inhibitors.
- You do not have severe kidney, liver, or heart failure, a history of pancreatitis, or type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking semaglutide (a weight-loss medication) before a catheter ablation procedure helps improve outcomes for people with atrial fibrillation and excess weight. If you qualify, it might help reduce the chance of the abnormal heart rhythm coming back.
This study looks at whether losing weight can help reduce the progression of atrial fibrillation (an irregular heartbeat). It might help people who are overweight and have AF symptoms.
This trial tests whether a weight-loss medication called tirzepatide (given as a shot) helps prevent atrial fibrillation from coming back after a catheter ablation procedure. It is for people who have both obesity and atrial fibrillation, and it may help improve heart health by reducing weight and inflammation.
This study tests whether a medication called semaglutide, which is used for weight loss, works better for people who also have binge eating. It aims to find the best treatment based on brain and behavior differences.
This study tests whether a weekly injection of tirzepatide (a medicine that helps with weight loss and blood sugar) can lower the chance of atrial fibrillation coming back after a heart procedure called catheter ablation. It may help people who are overweight or have obesity and are having this procedure.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.